VC-backed Aprea Therapeutics goes public
Boston and Stockholm-based Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, has raised about $85 million for its IPO after pricing its over 5.6 million shares at $15 per share. The stock began trading October 3, 2019 on the NASDAQ under the ticker symbol "APRE." J.P. Morgan, Morgan Stanley and RBC Capital Markets are the lead underwriters. Aprea's pre-IPO backers include Redmile Group, Rock Springs Capital, 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management and Karolinska Development AB.
3 October 2019•2 mins read
